CIBC World Markets’s UroGen Pharma URGN Stock Holding History

CIBC World Markets’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-75,000	Closed	-$1.13M	–	802
2024 Q1	$1.13M	Buy	+75,000	New	+$1.23M	0.01%	629

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CIBC World Markets's URGN Position: Q2 2024 in Review

CIBC World Markets sold out of UroGen Pharma (URGN) in Q2 2024, closing a stake of 75,000 shares — an estimated $1.13M sold.

CIBC World Markets first reported a position in URGN in Q1 2024 and held it in 1 quarter. The position peaked at $1.13M in Q1 2024. 115 funds tracked by Wall St. Rank hold URGN as of Q2 2024.

CIBC World Markets reported no remaining UroGen Pharma position as of Q2 2024 after selling out during the quarter.
CIBC World Markets sold 75,000 UroGen Pharma shares in Q2 2024, an estimated $1.13M.
CIBC World Markets first reported a position in UroGen Pharma in Q1 2024 and held it in 1 quarter.
CIBC World Markets's UroGen Pharma position peaked at $1.13M in Q1 2024.
115 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2024.

Based on CIBC World Markets's 13F filing for Q2 2024, filed 12 Aug 2024.